Johnson & Johnson faces fresh government inquiries about its marketing practices, even as the health-care giant works to finalize a potentially costly settlement of long-running U.S. probes of its promotion of the antipsychotic Risperdal and other drugs. J&J’s Janssen Pharmaceuticals unit in April received a letter from the U.S. Justice Department requesting documents related to the marketing and promotion of the antibiotic Doribax, J&J disclosed in its quarterly report filed last week with the Securities and Exchange Commission.
